Meg Alexander

Named a “Disruptor” and a “Rising Star” in her industry by PM360 and the Healthcare Business Women’s Association, Meg Alexander is a communications consultant on speed-dial of ~50 leading healthcare companies and their C-Suite executives. 

In her role leading Syneos Health Public Relations Reputation and Risk Management Practice, she has created award-winning corporate reputation programs and crafted launch strategies for the world’s leading biopharmaceutical companies.    

For nearly two decades, Meg has been passionate about enhancing and protecting the reputation of businesses and their leaders in a complex, evolving world. She has created strategies for iconic healthcare brands including: Pfizer, Novartis, Amgen, Janssen, Boehringer Ingelheim, Lilly, BioMarin, Merck, Alnylam, BioMarin, and many others. Through her experiences, she has honed deep disease category experience in chronic and rare diseases. 

Meg has expertise in media strategy and has placed CEOs, Chairmen and other C-Suite executives in the world’s most influential media outlets. She also has extensive experience helping business leaders with effective story telling – helping them showcase value to stakeholders. 

Her practice handled value communications for 20 percent of new drugs approved by the U.S. FDA in 2017 and 50 percent of value framework reviews from the Institute of Clinical and Economic Review (ICER).

Meg has been a go-to resource among her peers, and has been widely published in PM 360, Pharmaceutical Executive, O’Dwyers, Medical Marketing & Media and PR Week among others. She has also lectures at industry forums such as: BIO International, HBA, FDA/CMS Summit, Mass Bio Policy Breakfast, NJBIO CEO Forum, Financial Times, and many more.